GlassScriptPhysician profile
Jamie B Powers
NPI 1790246130
$3,145.86
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $655 · 2022: $2,066 · 2023: $236 · 2024: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $425.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,381.77 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $543.00 | 2021-2023 | Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $206.56 | 2021-2022 | |
| Gilead Sciences, INC. | $156.95 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $89.62 | 2021-2022 | |
| Celgene Corporation | $87.79 | 2022 | |
| Nestle Healthcare Nutrition INC. | $82.66 | 2022 | |
| Janssen Scientific Affairs, LLC | $81.34 | 2021 | |
| Janssen Biotech, INC. | $80.85 | 2021-2022 | |
| Qol Medical, LLC | $64.41 | 2022-2023 | Sucraid |
| Daiichi Sankyo INC. | $62.84 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $55.16 | 2022 | |
| Merck Sharp & Dohme LLC | $53.98 | 2021-2023 | Dificid |
| Regeneron Healthcare Solutions, INC. | $53.93 | 2022 | |
| Organon LLC | $40.86 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $27.56 | 2022 | |
| Amgen INC. | $18.48 | 2022 | |
| Glaxosmithkline, LLC. | $16.64 | 2022 | |
| Pfizer INC. | $16.26 | 2022 | |
| Redhill Biopharma INC. | $13.07 | 2021 | |
| Medtronic, INC. | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.